



SHEET 1 of 1

Form PTO-1 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
6248.4Serial No.
09/599,213**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicants
Erik H.F. Wong et al.Filing Date
June 22, 2000

Group APR 11 2001

TECH CENTER 1800/2900

U.S. PATENT DOCUMENTS

*Examiner Initials	Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Document Number	Publication Date	Country	Class	Subclass	Translation	
						Yes	No
asf	2,014,981	09/05/79	Great Britain				
	WO 99/52531	10/21/99	PCT				
	WO 99/52518	10/21/99	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

asf	E. Frigerio et al., <i>Pharmacokinetics of Reboxetine Enantiomers in the Dog</i> , Chirality, Vol. 9, pp. 303-06 (1997).
asf	G.D. Burrows et al., <i>Antidepressant Efficacy and Tolerability of the Selective Norepinephrine Reuptake Inhibitor Reboxetine: A Review</i> , J. Clin. Psychiatry, Vol. 59, Suppl. 14, 4 pages (1998).

::ODMA\PCDOCS\DOCS\490205\1

EXAMINER

WILLIAM R. A. JARVIS
PRIMARY EXAMINER

DATE CONSIDERED

10/5/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET 1 of 2

Form PTO-1449 (Modified)

JUL 20 2001

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.
6248.4

Serial No.
09/599,213


Applicants
Erik H.F. Wong et al.


Filing Date
June 22, 2000

Group


RECEIVED
JUL 23 2001
TECH. CENTER 1600/2900


U.S. PATENT DOCUMENTS							
*Examiner Initials	Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate	

FOREIGN PATENT DOCUMENTS							
*Examiner Initials	Document Number	Publication Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 99/20279	04-29-99	PCT	1	1		
	WO 99/58130	11-18-99	PCT				
	WO 01/26623	04-19-01	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)	
	B.E. Leonard, <i>Noradrenaline in Basic Models of Depression</i> , European Neuropsychopharmacology, Vol. 7, Suppl. 1, pp. S11-S16 (1997).
	Discussion, European Neuropsychopharmacology, Vol. 7, Suppl. 1, pp. S71 (1997).
	D. Healy et al., <i>The Clinical Pharmacologic Profile of Reboxetine: Does it Involve the Putative Neurobiological Substrate of Wellbeing?</i> , J. of Affective Disorders, Vol. 51, pp. 313-22 (1998).
	Anonymous, <i>Reboxetine - Another New Antidepressant</i> , Drugs and Therapeutics Bull., 36 (11) (Nov. 1998).
	S.A. Montgomery, <i>The Place of Reboxetine in Antidepressant Therapy</i> , J. of Clinical Psychiatry, Vol. 59, Suppl. 14, pp. 26-29 (1998).
	G.D. Burrows et al., <i>Antidepressant Efficacy and Tolerability of the Selective Norepinephrine Reuptake Inhibitor Reboxetine: A Review</i> , J. Clin. Psychiatry, Vol. 59, Suppl. 14, 4 pages (1998).

EXAMINER WILLIAM R. A. JARVIS PRIMARY EXAMINER	DATE CONSIDERED 10/5/01
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 6248.4	Serial No. 09/599,213	SHEET 2 of 2 RECEIVED JUL 23 2001 TECH CENTER 1600/2800
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Applicants Erik H.F. Wong et al.		JUL 23 2001 TECH CENTER 1600/2800
			Filing Date June 22, 2000	Group	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)	
	S. Kasper, <i>From Symptoms to Social Functioning: Differential Effects of Antidepressant Therapy</i> , International Clinical Psychopharmacology, Vol. 14, Suppl. 1, pp. S27-S31 (May 1999).
	International Search Report in PCT/US00/17256 dated July 12, 2001.

@PFDesktop\::ODMA/PCDOCS/DOCS/511298/1

EXAMINER	WILLIAM R. A. JARVIS PRIMARY EXAMINER	DATE CONSIDERED	10/5/01
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			